Danai.sam

#ชีวิตคือการซื้อเเบบเหมารวมทั้งสุขเศร้าเหงาทุกข์ประกอบกันเป็นชีวิตที่ไม่สามารถเเยกจากกันได้ #biology #MedTwitter #mmsm Translate science from bench to bedside🩸

[Talha Badar @TalhaBadarMD]

#weekend_review #leusm #venetoclax_4_AML 🧵

1/10 Venetoclax duration in #AML: toward a precision approach

Ven-HMA is standard therapy for older/unfit AML, but 2 questions remain unsettled:

https://t.co/v31e1TZxBh long should venetoclax be given within each cycle?
2.Can treatment eventually be stopped after a durable remission?

Increasingly, the answer may depend on genotype + depth of response, rather than one schedule for all.

[Vincent Rajkumar @VincentRK]

COMPREHENSIVE MYELOMA and PLASMA CELL DISORDERS REVIEW ARTICLE THREAD. Bookmark.

A collection of our recent review articles on the spectrum of plasma cell disorders.

1/ MGUS @NEJM

Link: https://t.co/y9cHVaPZgH

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

Excited and proud to share our special issue on #Leukemia that @ljmedeirosMD & I put together for @Human_Pathology We brought together incredible experts to write about the latest in the field.
13 articles, each one #hemepath GOLD💎! 1/14🧵
Starting with our intro to the issue https://t.co/f6ItnXL1id

[Luciano J Costa @End_myeloma]

For context on recent approval of Iberdomide based on MRD endpoint... #MMSM ⁦@BMS_Myeloma_US⁩
MRD accelerating myeloma drug development | Blood | American Society of Hematology https://t.co/PGlTsVGpVm

[Blood Journals Portfolio @BloodPortfolio]

This scoping review maps the earliest clinical signs of AL, ATTRwt, and ATTRv amyloidosis to improve early recognition and diagnosis. Read the full study in Blood Advances: https://t.co/qzY25NKEik

[Luciano J Costa @End_myeloma]

Slow ASH dash season for me, but not for you😄. So here goes 8 unsolicited pieces of advice as you prepare your @ASH_hematology abstract.

Thread!

[Blood Journals Portfolio @BloodPortfolio]

"Challenges in venous thromboembolism prophylaxis: a narrative review of East and Southeast Asian perspectives." Read the study in Blood Global Hematology ➡️ https://t.co/8mxmU1c5Mw #VTE

[Talha Badar @TalhaBadarMD]

1/ #weekend_review in the midst of #FIFA26 World Cup fever ⚽️

While the world is debating FIFA rules, referee bias, and game-changing decisions, another frontline playbook has been evolving in Ph+ ALL:

potent TKI + early blinatumomab + MRD-guided transplant decisions. 🧵

[Francesco Maura @FrancescoMaura4]

Our new study from the Polyethnic-1000 initiative is out! We investigated how genetic ancestry relates to multiple myeloma biology and outcomes. Several interesting and potentially provocative findings. Great collaboration @MayoClinic @MSKCancerCenter @nyulangone @SylvesterCancer

[Mark Wildgust (he/him) @MAWildgust]

Phenomenal presentation by @RahulBanerjeeMD here at @EHA_Hematology #EHA2026! Drop the 🎤 moment with the high risk data! @End_myeloma and @mvmateos broke the MajesTEC-3 data at #ASH25 and these data provide important information for 2L+ high risk patients. #MyCompany

[Ajay Major, MD, MBA @majorajay]

Does HD-MTX ppx reduce CNS relapse even in ultra-high-risk LBCL? #lymsm
- >1900 pts, all CNS-IPI 5-6; testicular, renal/adrenal, breast; ≥3 EN sites
- 3-yr CNS relapse: 9.3% (no HD-MTX) v 8.1% (HD-MTX), adjusted HR 1.13 [0.82, 1.57]
- no diff in isolated CNS relapse: 5.9% v 5.7%
- no diff in relapse rates for any high-risk subtypes
- DHL/THL not included
End of HD-MTX ppx, although DHL/THL is still a question. cc @tobyeyre82 @mattwilson2287
https://t.co/80zAeJmlXo

[Vincent Rajkumar @VincentRK]

Just out: Chronic myeloid leukemia: the definitive CML review and current treatment algorithms by @FadiHaddad_MD @DrHKantarjian @BloodCancerJnl #OpenAccess

https://t.co/U28uIP1Ltc

[Chaz Wargnier ♨️ @DataChaz]

Academic Researchers after reading these 4 guides

1/4

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Jame Abraham, MD, FACP @jamecancerdoc]

Absolutely practice changing!! One of the most stunning developments in the treatment of patients with metastatic pancreatic cancer !! It is one of the rare moments in oncology which you will always remember ! Like the imatinib, trastuzumab presentations @ASCO #ASCO26 @OncoAlert

[Daniel Auclair @AuclairDan]

2/ @ASCO #ASCO26 #myeloma #mmsm

- ERASMM Elra in HR SMM
https://t.co/VffWCRiZIq

- Optec/Optal
https://t.co/ykNRxGa3j5

- BelaDRd in TI NDMM
https://t.co/HOYhmYCCUd

- IEC-EC in CARTITUDE studies
https://t.co/3Ro4GHc6zE

[Raj Chakraborty @rajshekharucms]

The treatment landscape for AL #Amyloidosis has been transformed—but how do we assess prognosis and progression in the current era? We reviewed the current evidence on prognostic factors and biomarkers for hematologic and organ progression in this special report, out today in @BloodPortfolio. @Amyloidosis_ARC @YevgeniyBr @awechalekar @MathewMaurer @kristennhsu
https://t.co/UwdIaMm0d6

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

#COMy2026 #evangelosterpos summarizing one of most practice-changing (even if niche) data I’ve seen for bone-modifying agents in myeloma.

For moderate CKD, consider denosumab 60 mg not 120 mg to lower hypoCa.

Not randomized, but very reasonable given how severe hypoCa can be!

[Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD]

1/ 🧵 ANDROMEDA final analysis is practice-changing for newly diagnosed AL amyloidosis.

IMPORTANT tweets: 3/4 and 6 for clinicians who treats Amyloidosis

D-VCd = daratumumab + bortezomib/cyclophosphamide/dexamethasone.

With 61.4 months median follow-up, D-VCd improved depth of response, organ recovery, MOD-PFS, and OS. 🔥
#USMIRC #MedEd #medtwitter #mmsm #myeloma @USMIRCNEWS @US_HMC @MedwatchKate @Larvol @OncoAlert

[Meral Beksac @mbeksac56]

#COMY26 RESPONSE TO MYELOMA from the Blade criteria to the emerging 2026 IMS/IMWG criteria by @myelomaMD